Evidence map›Paper›PMID 30804153›Full record

ArticleIn vivo (Athens, Greece)

Palonosetron on Days 1 and 5

Yusuke Shimura, Kouji Izumi, Shingo Itai, Hiroaki Iwamoto, Hiroshi Yaegashi, Yukio Suga, Tsutomu Shimada, Atsushi Mizokami, Yoshimichi Sai

Open access · diamondAbstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yusuke ShimuraDepartment of Hospital Pharmacy, University Hospital, Kanazawa University, Kanazawa, Japan.
Kouji IzumiDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan azuizu2003@yahoo.co.jp.
Shingo ItaiDepartment of Hospital Pharmacy, University Hospital, Kanazawa University, Kanazawa, Japan.
Hiroaki IwamotoDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Hiroshi YaegashiDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Yukio SugaDepartment of Clinical Drug Informatics, Faculty of Pharmacy, Institute of Medical, Pharmaceutical & Health Sciences, Kanazawa University, Kanazawa, Japan.
Tsutomu ShimadaDepartment of Hospital Pharmacy, University Hospital, Kanazawa University, Kanazawa, Japan.
Atsushi MizokamiDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Yoshimichi SaiDepartment of Hospital Pharmacy, University Hospital, Kanazawa University, Kanazawa, Japan.
Kanazawa University · JPKanazawa University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe control of chemotherapy-induced nausea and vomiting during bleomycin, etoposide, and cisplatin (BEP) treatment is important for maintaining treatment intensity. The effects of palonosetron and granisetron were compared in BEP chemotherapy. PATIENTS AND

methodsThe administration of palonosetron on days 1 and 5 (Pal method) and granisetron daily (days 1-5, Gra method) were compared in terms of their efficacy and cost-effectiveness.

resultsAdditional rescue antiemetic agents were used in 15 of 32 and 30 of 30 cycles in the Pal and Gra method groups, respectively (p<0.05). The complete response rate, defined as no vomiting and no rescue agent usage, in each cycle, was 50% and 0% in the Pal and Gra method groups, respectively (p<0.05). The average cost of antiemetic agents in a cycle was 50,759 and 54,555 yen in the Pal and Gra method groups, respectively (p<0.05).

conclusionThe Pal method may be the standard method in BEP.

Indexed as

AdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBleomycinCisplatinDrug Administration ScheduleEtoposideFemaleGranisetronHumansMaleMiddle AgedNauseaNeoplasms, Germ Cell and EmbryonalPalonosetronBleomycinCisplatinEtoposideGranisetronPalonosetronchemotherapy-induced nausea and vomitingGerm cell tumourgranisetronpalonosetron

Identifiers

PMID30804153
PMCPMC6506324
OpenAlexW2916840035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.